Objective:
To explore innovations impacting the scalability, consistency, and commercial readiness of cell and gene therapy manufacturing.
Approach:
- Industry Insights: Experts from various companies discuss advancements and challenges in manufacturing cell and gene therapies.
Key Findings:
- Manufacturing is a significant barrier to the widespread adoption of cell and gene therapies.
- Stable cell lines, process intensification, AI-driven process modeling, operational excellence, and quality-by-design are key tools for increasing output.
- Flexible manufacturing models and stronger analytical technologies can help adapt production to various therapeutic modalities.
Conclusion:
The insights highlight the ongoing challenges and innovations in the manufacturing sector of cell and gene therapies.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
